Trends in Cancer is a leading reviews journal covering advances in cancer research and oncology published by Cell Press. Tweets by Editor Danielle Loughlin.
A holy grail for our lab has been tracking myeloid cells in human tumors in the same way that we track T and B cells with TCR/BCR.
@vincentzliu and @CalebLareau solved it!
We developed Mitotrek using scATAC-seq + mitochondrial DNA to do exactly this. Using Mitotrek, we find that new myeloid cells clones constantly infiltrate the tumor via circulating monocytes — and that their macrophage or dendritic cell fate is epigenetically programmed before tumor entry.
@10xGenomics@parkerici@CancerResearch@TheMarkFdn
https://t.co/Y37qbyw3F5
Can ctDNA transform the management of biliary tract cancers? Our new @trendscancer forum paper outlines the promise, limitations, and path toward clinical implementation. Grateful to all collaborators who made this work possible. @PrecisionBTCnet@atuvibi
https://t.co/vNU7DazoKM
Be part of the Hallmarks of cancer legacy.
Join our distinguished keynote speakers Johanna Joyce @Joycelab & Faisal Mahmood @AI4Pathology in Sitges, Spain, November 1–3, 2026.
Abstract deadline: June 26, 2026
🔗https://t.co/lCv4t62UbC
@CellPressEvents#CSHallmarks2026
🚨 Out today in Cell! @CellCellPress
Path2Space: #AI that predicts spatial transcriptomics (ST) from H&E pathology, enabling spatial biomarker discovery in #BreastCancer at scale.
📄 https://t.co/GtrmH9zIDs
🧵1/8
🧬 #ScienceSaturday
❓ What if cancer treatment could target not only tumor cells, but also the tumor’s stromal support: non-malignant, non-cancerous cells within the tumor microenvironment, that actively help cancer grow, spread, and resist treatment?
➡️ In a new study published in @CellCellPress, researchers identified uPAR, a cell-surface protein linked to aggressive tumor behavior, as a marker found on both solid tumor cells and the fibrotic, immune-suppressive environment that helps sustain them.
➡️ The team developed uPAR-targeted CAR T cells that attacked both tumor cells and their supportive stroma, leading to durable tumor regression across multiple cancer models, including metastatic disease.
➡️ They also found that senescence-inducing therapies, like chemotherapy, increased uPAR expression and made tumors even more vulnerable to CAR T cell treatment.
🌟 This dual-targeting strategy could help overcome some of the biggest barriers to CAR T therapy in solid tumors, including immune suppression and treatment resistance.
🔗 Read the study: https://t.co/dvHrEzUZ7F
@ZedaZhang@Aveline_Filliol@LoweLabMSKCC
See what the organizers have to say about @CellPressEvents#CSHallmarks2026 and join them in Spain, Nov 1–3, 2026, to celebrate the convergence of basic and translational science, spark new connections, and shape the future of precision oncology.
https://t.co/kf2WYRrog5
1/ Thrilled to share our new paper, out today in @Nature: "Non-invasive profiling of the tumour microenvironment with spatial ecotypes".
Paper (open access): https://t.co/EujZFqU7wi
New @Nature study: >50% of lung cancer metastases are seeded by other metastases, not the primary tumor. This "seeding from seeding" reveals a complex evolutionary cascade that allows cancer to colonize the body.
https://t.co/lYUyfRYOcP
Meet Trends Open: a new multidisciplinary, open-access reviews journal for commentaries and fresh perspectives across life, physical, health, sustainability, and applied sciences—welcoming early-career and established researchers. https://t.co/9rjgUT1K7r
From our @Nature paper, where we demonstrate profound molecular heterogeneity even between two synchronous liver metastases. This is the challenge of advanced #PancreaticCancer. Targeting truncal mutations like KRAS overcomes some of this recalcitrance.
https://t.co/JTKFdxYcMU
With news of @KeloniaTx's acquisition by $LLY yesterday, a fitting time to share our Review on in vivo CAR-T engineering, out now in @trendscancer! We summarize state-of-the-art approaches to in vivo engineering and open questions still ahead. Full text link in comments!
Reflect on 25 years of the Hallmarks of Cancer framework in this special issue from @CellCellPress https://t.co/nqS98w3ZjP
To continue the conversation, join us @CellPressEvents Hallmarks of Cancer, November 1–3, 2026, Sitges, Spain.
#CSHallmarks2026
Thrilled to share our new review article on #p53 and #plasticity in @trendscancer - p53: defender of lineage fidelity and foe of plasticity in cancer and regeneration @arati_rajeevan https://t.co/83q2cYFa9N